OYST - Oyster Point Pharma inks deal with Adaptive Phage Therapeutics in ophthalmic diseases

Oyster Point Pharma (OYST) has formed research collaboration with Adaptive Phage Therapeutics ((APT)) to leverage APT’s PhageBank technology for the development of potential treatments for multiple ophthalmic diseases. Under the terms of the agreement, Oyster Point Pharma has the option and certain rights to obtain an exclusive license to develop and commercialize APT’s PhageBank technology.If such option is exercised, Oyster Point has agreed to pay APT potential milestones and tiered royalties of net sales, if a licensed phage therapy is approved by the FDA.APT retains production rights to PhageBank and will supply Oyster Point product at an agreed upon cost-plus model. Oyster Point plans to discuss additional details at the upcoming Analyst Day, planned for July 15, 2021.

For further details see:

Oyster Point Pharma inks deal with Adaptive Phage Therapeutics in ophthalmic diseases